Nanoparticle-Encapsulated Curcumin Inhibits Diabetic Neuropathic Pain Involving the P2Y12 Receptor in the Dorsal Root Ganglia

Jia, Tianyu; Rao, Jingan; Zou, Lifang; Zhao, Shanhong; Yi, Zhihua; Wu, Bing; Li, Lin; Yuan, Huilong; Shi, Liran; Zhang, Chunping; Gao, Yun; Liu, Shuangmei; Xu, Hong; Liu, Hui; Liang, Shangdong; Li, Guilin

doi:10.3389/fnins.2017.00755

Cited by 75 publications

(56 citation statements)

References 63 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Devadasu and co-workers formulated curcumin-loaded PLGA nanoparticles for oral delivery, which exhibited improved bioavailability of curcumin and better therapeutic efficacy in the management of hyperlipidaemia, and inflammation in diabetic rats [197]. An amphiphilic polymer prepared by the polymerization of methyaluminoxane (MAO), poly-(ethylene glycol) methacrylate (PEGMA), and 2-(dimethylamino)ethyl methacrylate (DMAEMA) was found to be a potential nanocarrier for encapsulating curcumin [198]. The curcumin-loaded nanoparticles were found to attenuate diabetic neuropathy via suppressing interleukin-1β (IL-1β), connexin43, and phosphorylated protein kinase B (Akt) expressions in dorsal root ganglia and downregulating purinergic 2 (P2) Y12 receptor mRNA expression in satellite glial cells of diabetic rats [198].…”

Section: Curcuminmentioning

confidence: 99%

“…An amphiphilic polymer prepared by the polymerization of methyaluminoxane (MAO), poly-(ethylene glycol) methacrylate (PEGMA), and 2-(dimethylamino)ethyl methacrylate (DMAEMA) was found to be a potential nanocarrier for encapsulating curcumin [198]. The curcumin-loaded nanoparticles were found to attenuate diabetic neuropathy via suppressing interleukin-1β (IL-1β), connexin43, and phosphorylated protein kinase B (Akt) expressions in dorsal root ganglia and downregulating purinergic 2 (P2) Y12 receptor mRNA expression in satellite glial cells of diabetic rats [198]. Curcumin-loaded polylactic acid (PLA)-polyethylene glycol (PEG) polymeric nanoparticles were found to be effective through the oral route in reciprocating hyperglycaemia, hypoinsulinemia, and diabetes-provoked hepatotoxicity more effectively than free curcumin [199].…”

Section: Curcuminmentioning

confidence: 99%

See 1 more Smart Citation

Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy

Dewanjee

Chakraborty

Mukherjee

et al. 2020

IJMS

View full text Add to dashboard Cite

Diabetes mellitus is a life-threatening metabolic syndrome. Over the past few decades, the incidence of diabetes has climbed exponentially. Several therapeutic approaches have been undertaken, but the occurrence and risk still remain unabated. Several plant-derived small molecules have been proposed to be effective against diabetes and associated vascular complications via acting on several therapeutic targets. In addition, the biocompatibility of these phytochemicals increasingly enhances the interest of exploiting them as therapeutic negotiators. However, poor pharmacokinetic and biopharmaceutical attributes of these phytochemicals largely restrict their clinical usefulness as therapeutic agents. Several pharmaceutical attempts have been undertaken to enhance their compliance and therapeutic efficacy. In this regard, the application of nanotechnology has been proven to be the best approach to improve the compliance and clinical efficacy by overturning the pharmacokinetic and biopharmaceutical obstacles associated with the plant-derived antidiabetic agents. This review gives a comprehensive and up-to-date overview of the nanoformulations of phytochemicals in the management of diabetes and associated complications. The effects of nanosizing on pharmacokinetic, biopharmaceutical and therapeutic profiles of plant-derived small molecules, such as curcumin, resveratrol, naringenin, quercetin, apigenin, baicalin, luteolin, rosmarinic acid, berberine, gymnemic acid, emodin, scutellarin, catechins, thymoquinone, ferulic acid, stevioside, and others have been discussed comprehensively in this review.

show abstract

Section: Curcuminmentioning

confidence: 99%

Section: Curcuminmentioning

confidence: 99%

Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy

Dewanjee

Chakraborty

Mukherjee

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In addition, an alternative curcumin delivery system, self-nano-emulsifying drug delivery system (SNEDDS) curcumin, reversed, in male SD rat model of DPN, the mechanical hypersensitivity to hot and cold measured by von Frey test and tail flick hot and cold immersions, respectively [ 51 ]. Nanoparticle-encapsulated curcumin (curcumin-polybutylcyanoacrylate nanoparticle-encapsulated particles: PEGMA-DMAEMA-MAO) has also been investigated in DPN male SD rat model and showed a reduction of both thermal and mechanical hypersensitivity [ 52 ]. Other models widely used in the study of neuropathic pain are the chronic constriction injury (CCI) and nerve ligature models.…”

Section: Curcumin Studies In Animal Models Of Pnmentioning

confidence: 99%

Key Developments in the Potential of Curcumin for the Treatment of Peripheral Neuropathies

et al. 2020

View full text Add to dashboard Cite

Peripheral neuropathies (PN) can be triggered after metabolic diseases, traumatic peripheral nerve injury, genetic mutations, toxic substances, and/or inflammation. PN is a major clinical problem, affecting many patients and with few effective therapeutics. Recently, interest in natural dietary compounds, such as polyphenols, in human health has led to a great deal of research, especially in PN. Curcumin is a polyphenol extracted from the root of Curcuma longa. This molecule has long been used in Asian medicine for its anti-inflammatory, antibacterial, and antioxidant properties. However, like numerous polyphenols, curcumin has a very low bioavailability and a very fast metabolism. This review addresses multiple aspects of curcumin in PN, including bioavailability issues, new formulations, observations in animal behavioral tests, electrophysiological, histological, and molecular aspects, and clinical trials published to date. The, review covers in vitro and in vivo studies, with a special focus on the molecular mechanisms of curcumin (anti-inflammatory, antioxidant, anti-endoplasmic reticulum stress (anti-ER-stress), neuroprotection, and glial protection). This review provides for the first time an overview of curcumin in the treatment of PN. Finally, because PN are associated with numerous pathologies (e.g., cancers, diabetes, addiction, inflammatory disease...), this review is likely to interest a large audience.

show abstract

“…As early as 2 weeks after STZ injection, Hanani et al (2014) found a significant increase in the expression of the glial fibrillary acidic protein (GFAP) in mouse and rat activated SGCs. SGC activation was also characterized by an increased expression of P2Y12 receptors, which participate to the sandwich synapse mechanism, and connexin 43, which promotes transglial spread of excitation through the gap junctions (Jia et al, 2018).…”

Section: Structural Relationship Between Sensory Neurons and Sgcs Imentioning

confidence: 99%

Cytoarchitectural analysis of the neuron‐to‐glia association in the dorsal root ganglia of normal and diabetic mice

et al. 2020

View full text Add to dashboard Cite

Dorsal root ganglia (DRGs) host the somata of sensory neurons which convey information from the periphery to the central nervous system. These neurons have heterogeneous size and neurochemistry, and those of small-to-medium size, which play an important role in nociception, form two distinct subpopulations based on the presence (peptidergic) or absence (non-peptidergic) of transmitter neuropeptides. Few investigations have so far addressed the spatial relationship between neurochemically different subpopulations of DRG neurons and glia. We used a whole-mount mouse lumbar DRG preparation, confocal microscopy and computer-aided 3D analysis to unveil that IB4 + non-peptidergic neurons form small clusters of 4.7 ± 0.26 cells, differently from CGRP + peptidergic neurons that are, for the most, isolated (1.89 ± 0.11 cells). Both subpopulations of neurons are ensheathed by a thin layer of satellite glial cells (SGCs) that can be observed after immunolabeling with the specific marker glutamine synthetase (GS). Notably, at the ultrastructural level we observed that this glial layer was discontinuous, as there were patches of direct contact between the membranes of two adjacent IB4 + neurons. To test whether this cytoarchitectonic organization was modified in the diabetic neuropathy, one of the most devastating sensory pathologies, mice were made diabetic by streptozotocin (STZ). In diabetic animals, cluster organization of the IB4 + non-peptidergic neurons was maintained, but the neuro-glial relationship was altered, as STZ treatment caused a statistically significant increase of GS staining around CGRP + neurons but a reduction around IB4 + neurons. Ultrastructural analysis unveiled that SGC coverage was increased at the interface between IB4 + cluster-forming neurons in diabetic mice, with a 50% reduction in the points of direct contacts between cells. These observations demonstrate the existence of a structural plasticity of the DRG cytoarchitecture in response to STZ.

show abstract

Nanoparticle-Encapsulated Curcumin Inhibits Diabetic Neuropathic Pain Involving the P2Y12 Receptor in the Dorsal Root Ganglia

Cited by 75 publications

References 63 publications

Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy

Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy

Key Developments in the Potential of Curcumin for the Treatment of Peripheral Neuropathies

Cytoarchitectural analysis of the neuron‐to‐glia association in the dorsal root ganglia of normal and diabetic mice

Contact Info

Product

Resources

About